ClinicalTrials.gg
Status unknownNCT03374839Nivo-TILUpdated May 6, 2022

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

A Phase 1/2 interventional study of TIL + IL-2 + Nivolumab in Melanoma, sponsored by Nantes University Hospital. Status unknown at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Nantes University Hospital · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies testing Interleukin-2 in Melanoma — none open to participants now, 2 under way, none of them phase 3. Interleukin-2 · Melanoma.

Planned enrollment
24th of 41
11 · median 15
Started
2018
with 4 others
Phase 1/2
6 of 43
none open now
Registered
35th of 43
by date
Lead sponsor
2 of 43
Nantes University Hospital

Among the 43 studies testing Interleukin-2 in Melanoma, this one is the 24th largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 1/2, and was the 35th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 43 studies testing Interleukin-2 in Melanoma is open now. The open studies under Melanoma, anywhere →

About Interleukin-2

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing Interleukin-2 in Melanoma as a file.
02

Study summary

To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the self-destructive process.

A clinically relevant immune escape mechanism in melanoma is the activation of the Programmed cell Death-1 (PD-1) receptor on infiltrating T cells. By blocking PD-1 receptors with anti-PD-1 monoclonal antibodies (mAbs), T-cells are unaffected by the PD-L1 expressed on tumor cells and the patients T cells are free to respond to melanoma antigens and attack tumor cells. So the objective of this trial is to evaluate the safety and the efficacy of a combined therapy Nivolumab and adoptive T cell therapy in metastatic melanoma patients.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • over 18 years old with a weight ≥ 40 kg
  • Patients must have signed
  • Patients with stage IIIb, IIIc or IV melanoma (AJCC 6th edition) with at least two lesions (lymph nodes relapse, or in transit metastasis, or unresectable cutaneous metastases, or visceral metastases except bone and ) including one easily accessible and no more than 2 of melanoma at the metastatic stage.
  • Patients with a melanoma expressing a Braf V600 mutation can be included
  • Measurable/assessable disease in 28 days which precede the first administration of the treatment
  • A negative pregnancy test for women with
  • (ECOG) of 0-1, > 80%
  • Laboratory results:

≥ 10 g/dl or ≥ 6,25 mmol/l; Neutrophils ≥ 1500/μl; Leukocytes ≥ 4000/μl; Lymphocytes ≥ 700/μl; Blood ≥ 100.000/μl; Serum creatinine ≤ 1.5 x superior normal value or (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula); Serum ≤ 2.0 mg/dl or ≤ 34.2 mol/l; Total bilirubin ≤ 1.5 x superior normal value (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3mg/dL); (AST) and Alanine aminotransferase (ALT) ≤ 2 x superior normal value; Lactate dehydrogenase (LDH) ≤ 1.5 x superior normal value

  • Subjects affiliated to an appropriate health insurance
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of during the clinical trial. Furthermore WOCBP will be instructed to adhere to contraception for a period of 5 months after the last dose of Nivolumab.
  • Men who are sexually active with WOCBP will be instructed to adhere to contraception during the clinical trial and for a period of 7 months after the last dose of Nivolumab.
  • Women who are not of childbearing potential (ie, who are or surgically sterile) as well as azoospermic men do not require contraception.

Non inclusion Criteria:

  • Brain or bone metastases
  • Ocular melanoma
  • Chemotherapy or radiotherapy within 4 weeks before baseline (6 weeks for nitroso-ureas and mitomycin C)
  • for the use of vasopressor agents
  • For female: the patient is pregnant or breastfeeding or not using contraception
  • For men: the patient is sexually active with WOCBP and not using contraception
  • History or current manifestations of severe progressive heart disease (congestive heart failure, coronary artery disease, uncontrolled arterial hypertension, serious rhythm disorders or signs of previous myocardial infarction)
  • Patients should be excluded if they have had prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways except in the context of adjuvant or
  • History of allergies and Adverse Drug Reaction:

    • to human albumin, TIL
    • Hypersensitivity to Nivolumab or related excipients
    • History of severe hypersensitivity reaction to any monoclonal antibody
    • Hypersensitivity to aldesleukin or to one of Proleukin excipients
  • History of chronic disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, etc...) except patient with active vitiligo or a history of vitiligo.
  • History of uveitis or melanoma-associated retinopathy
  • History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea.
  • Presence of a second active cancer, with the exception of an in situ cervical cancer or a skin cancer different from the treated melanoma
  • Unchecked thyroid dysfunction
  • Any serious, acute or chronic illness id est active infection asking for antibiotics administration, coagulation's disorders, or any state asking for an unauthorized concomitant treatment described in this study
  • Patients should be excluded if they have a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days before study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
  • Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")

Exclusion criteria

Exclusion Criteria:

* Positive viral serology for (human immunodeficiency virus) 1/2, p24 Ag, HTLV1, HTLV2, B and C hepatitis or syphilis

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (estimated)

Study arms

  • Experimental
    TIL + IL-2 + Nivolumab

    A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies. For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL.

    Drug: TIL + IL-2 + Nivolumab

Interventions

  • DrugTIL + IL-2 + Nivolumab

    Drug pages: Interleukin-2 · Nivolumab

    The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52. Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18. The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events

    Clinical and biological criteria defined by the NCI (Common Terminology Criteria for Adverse Events - version 4.0, may 2009, http://ctep.cancer.gov)

    Time frame: Within 12 months

Secondary outcomes

  1. Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab

    The overall tumor response will be evaluated according to the guidelines for Response Evaluation Criteria in Solid Tumors (RECIST1.1) and immune-related Response Criteria (irRC)

    Time frame: At 12 months

  2. Duration of the clinical response

    Time interval between the evaluation of the first objective response and the first evaluation of disease progression or death, whichever occurs first

    Time frame: Within 12 months of follow-up

  3. Progression-free survival

    Evaluation of the progression-free survival of patients treated with adoptive T cell therapy in combination with intravenous injections of Nivolumab

    Time frame: From the date of the first infusion of Nivolumab until the date of the first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months

  4. Overall survival

    Evaluation of the overall survival of patients treated with adoptive T cell therapy in combination with intravenous injections of Nivolumab

    Time frame: From the date of the first infusion of Nivolumab until the date of death, assessed up to 12 months

  5. Specific immune monitoring n°1: Evaluate the fraction of TIL specific to Melan-A and MELOE-1

    Evaluation of the fraction of TIL specific to two Human Leukocyte Antigen (HLA)-peptide complexes (Melan-A and MELOE-1)

    Time frame: Week 14 + week 18

  6. Specific immune monitoring n°2: Evaluate the proportion of regulatory T cells

    Evaluation of the proportion of regulatory T cells

    Time frame: Day 0 (1st Nivolumab injection) + week 14 + week 18 + week 26 + week 38 + at the date of disease progression assessed up to 12 months

  7. Specific immune monitoring n°3: Analyse the expression of tumor antigens

    Analysis of the expression of tumor antigens

    Time frame: Week 10 + week 38

  8. Specific immune monitoring n°4: Analyse the expression of immunosuppressive cytokines

    Analysis of the expression of immunosuppressive cytokines

    Time frame: Week 10 + week 38

  9. Specific immune monitoring n°5: Analyse the expression of indoleamine 2,3-dioxygenase (IDO)

    Analysis of the expression of IDO

    Time frame: Week 10 + week 38

  10. Specific immune monitoring n°6: Analyse the expression of FoxP3

    Analysis of the expression of FoxP3

    Time frame: Week 10 + week 38

  11. Specific immune monitoring n°7: Analyse the expression of regulatory molecules

    Analysis of the expression of regulatory molecules

    Time frame: Week 10 + week 38

  12. Specific immune monitoring n°8: Analyse the mutations of BRAF

    Analysis of BRAF mutations

    Time frame: Week 10 + week 38

  13. Specific immune monitoring n°9: Analyse the mutations of Neuroblastoma Ras viral oncogene homolog (NRAS)

    Analysis of NRAS mutations

    Time frame: Week 10 + week 38

  14. Specific immune monitoring n°10: Analyse the mutations of proto-oncogene ckit (cKit)

    Analysis of cKit mutations

    Time frame: Week 10 + week 38

  15. Specific immune monitoring n°11: Determine the percentage of reactive T cells in the expanded cells

    Produce tumor cell line and determine the percentage of reactive T cells in the expanded cells

    Time frame: Week 10

  16. Specific immune monitoring n°12: Determine the phenotype of the expanded T cells

    Produce tumor cell line and determine the phenotype of the expanded T cells

    Time frame: Week 10

  17. Specific immune monitoring n°13: Test TIL reactivity

    Produce tumor cell line and test TIL reactivity

    Time frame: Week 10

07

Study locations

1 of 1 sites recruiting
  • Nantes University Hospital
    Nantes, 44000, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2018 (actual). Primary completion is estimated for Jan 2024, 71 months after the start.

Of 85 non-industry phase 1/2 interventional studies under Melanoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 98. This study's planned 71 months is above that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 15, 2017
StartActual
Feb 12, 2018
Primary completionEst.
Jan 2024
CompletionEst.
Jan 2024
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03374839
Responsible party
Sponsor
First posted
Dec 15, 2017
Start date
Feb 12, 2018
Primary completion
Jan 2024 (estimated)
Completion
Jan 2024 (estimated)
Last update
May 6, 2022

Study contacts

Amir Khammari, PhD
Contact
amir.khammari@chu-nantes.fr
(+33) (0)2 40 08 32 80
Brigitte Dréno, MD, PhD
Contact
brigitte.dreno@wanadoo.fr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interleukin-2 · Nivolumab

Start the discussion